Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
Bueno Ramirez, Susan Marcela,Kalergis Parra, Alexis Mikes,Lay Remolcoi, Margarita Kam-Lem
申请号：
AU2016402264
公开号：
AU2016402264A1
申请日:
2016.04.15
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention relates to a pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, the agent being selected from monoclonal antibodies, biological molecules or synthetic molecules. More specifically, the neutralising agents are anti-TSLP, anti-TSLPR, anti-OX40L and anti-CD177 humanised monoclonal antibodies. Also described is the use of the composition for preparing a drug for treating or reducing the symptoms and disease in patients infected with human metapneumovirus (HMPV).
